A Reversal for Blueprint Medicines Corporation (NASDAQ:BPMC) Is Not Near. The Stock Has Rise in Shorts

September 17, 2017 - By Henry Gaston

 A Reversal for Blueprint Medicines Corporation (NASDAQ:BPMC) Is Not Near. The Stock Has Rise in Shorts

The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) registered an increase of 12.4% in short interest. BPMC’s total short interest was 2.46 million shares in September as published by FINRA. Its up 12.4% from 2.19 million shares, reported previously. With 407,200 shares average volume, it will take short sellers 6 days to cover their BPMC’s short positions. The short interest to Blueprint Medicines Corporation’s float is 9.29%.

The stock increased 2.23% or $1.26 on September 15, reaching $57.82. About 825,820 shares traded or 99.67% up from the average. Blueprint Medicines Corp (NASDAQ:BPMC) has risen 128.96% since September 17, 2016 and is uptrending. It has outperformed by 112.26% the S&P500.

Blueprint Medicines Corporation is a biopharmaceutical company. The company has market cap of $2.26 billion. The Firm focuses on patients with genomically defined diseases driven by abnormal kinase activation. It currently has negative earnings. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options.

Blueprint Medicines Corp (NASDAQ:BPMC) Ratings Coverage

Among 6 analysts covering Blueprint Medicine Corp (NASDAQ:BPMC), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicine Corp had 11 analyst reports since February 22, 2016 according to SRatingsIntel. As per Tuesday, June 6, the company rating was maintained by Jefferies. The stock has “Buy” rating by Cowen & Co on Wednesday, August 2. The rating was maintained by Jefferies on Monday, September 4 with “Buy”. The stock of Blueprint Medicines Corp (NASDAQ:BPMC) has “Buy” rating given on Tuesday, June 6 by Cowen & Co. Canaccord Genuity maintained Blueprint Medicines Corp (NASDAQ:BPMC) on Tuesday, June 6 with “Buy” rating. The company was initiated on Friday, August 5 by Canaccord Genuity. The firm has “Buy” rating by Goldman Sachs given on Monday, March 13. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, August 2. On Friday, May 27 the stock rating was initiated by Raymond James with “Outperform”. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”.

More notable recent Blueprint Medicines Corp (NASDAQ:BPMC) news were published by: Prnewswire.com which released: “Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of …” on September 10, 2017, also Seekingalpha.com with their article: “Blueprint Medicines’ (BPMC) CEO Jeff Albers on Q2 2017 Results – Earnings Call …” published on August 02, 2017, Prnewswire.com published: “Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of …” on May 17, 2017. More interesting news about Blueprint Medicines Corp (NASDAQ:BPMC) were released by: Prnewswire.com and their article: “Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in …” published on June 05, 2017 as well as Prnewswire.com‘s news article titled: “Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 …” with publication date: November 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.